Non-human primates in medical research and drug development: A critical review

Biogenic Amines

Volumn 19, Issue 4-6, 2005, Pages 235-255

  Bailey, Jarrod ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Animal; Monkeys; NHP; Primates

Indexed keywords

ACETYLSALICYLIC ACID; ALZHEIMER DISEASE VACCINE; AMRINONE; BENOXAPROFEN; CARBENOXOLONE; HORMONE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMATINIB; INDOPROFEN; ISOPRENALINE; LEVODOPA; NUCLEOSIDE ANALOG; POLIOMYELITIS VACCINE; PROTEINASE INHIBITOR; THALIDOMIDE;

ALZHEIMER DISEASE; ARTHRITIS; ASTHMA; BIRTH DEFECT; BLEEDING; BRAIN DEPTH STIMULATION; BREAST CANCER; CLINICAL TRIAL; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG FATALITY; DRUG INDUSTRY; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG RESEARCH; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HEART DISEASE; HEART FAILURE; HORMONE SUBSTITUTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKEMIA; MEDICAL RESEARCH; NONHUMAN; PARKINSON DISEASE; POLIOMYELITIS; PREDICTION; PRENATAL DRUG EXPOSURE; PRIMATE; REVIEW; SPECIES DIFFERENCE; STOMACH ULCER; STROKE; TERATOGENICITY; TOXICITY TESTING; UNITED KINGDOM; VACCINATION;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; PRIMATES;

EID: 29444441457     PISSN: 01688561     EISSN: None     Source Type: Journal    
DOI: 10.1163/156939105774647385     Document Type: Review

References (91)

1. Animal Procedures Committee (2002). The use of primates under the Animals (Scientific Procedures) Act (1986). Analysis of current trends with particular reference to regulatory toxicology.
2. Anzai, T., et al. (2003). Comparative sequencing of human and chimpanzee MHC class I regions unveils insertions/deletions as the major path to genomic divergence, Proc. Natl. Acad. Sci. USA 100, 7708-7713.
3. Arluke, A. (1994). The ethical socialization of animal researchers, Lab. Animals (June), 30-35.
4. Bailey, J., Knight, A. and Balcombe, J. (2005). The future of teratology research is in vitro, Biogenic Amines 19, 97-145.
5. Benabid, A. L., Pollak, P., Louveau, A., Henry, S. and de Rougemont, J. (1987). Combined (thalamotomy and stimulation) stereotactic surgery of the VIM thalamic nucleus for bilateral Parkinson disease, Appl. Neurophysiol. 50, 344-346.
6. Benabid, A. L., Pollak, P., Hommel, M., Gaio, J. M., de Rougemont, J. and Perret, J. (1989). Treatment of Parkinson tremor by chronic stimulation of the ventral intermediate nucleus of the thalamus, Rev. Neurol. (Paris) 145, 320-323 (in French).
7. Bolognesi, D. P. (1994). A live-virus AIDS vaccine? J. NIH Res. 6, 59-62.
8. Boyd Group Papers (2002). The Use of Non-Human Primates in Research and Testing, http://www.boyd-group.demon.co.uk.
9. Brimblecombe, R. (1981). In: Risk-Benefit Analysis in Drug Research, Proceedings of an International Symposium Held at the University of Kent at Canterbury, England, 1980, Cavalla, J. F. (Ed.), p. 153. Society for Drug Research, Great Britain.
10. British Association for Tissue Banking website: http://www.batb.org.uk/
11. Caldwell, J. (1992). Species differences in metabolism and their toxicological significance, Toxicol. Lett. 64, 106.
12. Carson, S., Scheimbe, J., Mackars, A. and Vogin, E. E. (1971). Continuing toxicologic reassessment of isoprenaline aerosols, Pharmacologist 13, 272.
13. Chiba, M., et al. (2000). Comparative in vitro metabolism of indinavir in primates - a unique stereoselective hydroxylation in monkeys, Xenobiotica 30, 117-129.
14. Conner, J. M. and Tuszynski, M. H. (2000), in: Central Nervous System Diseases: Innovative Animal Models from Lab to Clinic, Emerich, D. F., Dean III, R. L. and Sanberg, P. R. (Eds), p. 66. Humana Press, Totowa, New Jersey, USA.
15. DeVita, V. T. Jr., Hellman, S. and Rosenberg, S. A. (1992). AIDS Etiology, Diagnosis, Treatment, and Prevention, 3rd ed. J. B. Lippincott, Philadelphia, USA.
16. Druker, B. J. and Lydon, N. B. (2000). Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukaemia, J. Clin. Invest. 105, 3-7.
17. Druker, B. J., Tamura, S., Buchdunger, E., et al. (1996). Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells, Nature Med. 2, 561-566.
18. Dunayer, J. (2005). Censored: Faculty who oppose vivisection, Z Magazine (April) 57-60, www.zmag.org
19. Eason, C. T., et al. (1987). The effect of amrinone on platelets - cause and significance, Human Toxicol. 6, 436.
20. Eason, C. T., et al. (1990). The importance of pharmacokinetic and receptor studies in drug safety evaluation, Regulat. Toxicol. Pharmacol. 11, 288-307.
21. Emory University Health Sciences Center press release, 13 October 2003.
22. Enard, W., Khaitovich, P. and Klose, J., et al. (2002). Intra- and interspecific variation in primate gene expression patterns, Science 296, 340-343.
23. European Agency for the Evaluation of Medicinal Products (EMEA) (2003). Position paper on non-clinical safety studies to support clinical trials with a single microdose. CPMP/SWP/2599/02.
24. Gagneux, P. and Varki, A. (2001). Genetic differences between humans and great apes, Molecular Phylogenetics and Evolution 18, 2-13.
25. Gallo, R. (1991). Virus Hunting. Basic Books, Harper Collins, London.
26. Geissler, J. F., Roesel, J. L., Meyer, T., et al. (1992). Benzopyranones and benzothiopyranones: a class of tyrosine protein kinase inhibitors with selectivity for the v-abl kinase, Cancer Research 52, 4492-4498.
27. Gluck, J. P. and Kubacki, S. R. (1991). Animals in biomedical research: the undermining effect of the rhetoric of the besieged, Ethics and Behavior 1, 157-173.
28. Gray, S. (2003). Breast cancer and hormone-replacement therapy: The Million Women Study, Lancet 362, 1332.
29. Greaves, P., Williams, A. and Eve, M. (2004). First dose of potential new medicines to humans: how animals help, Nature Reviews Drug Discovery 3, 226-236.
30. Guela, C., Wu, C.-K., Saroff, D., Lorenzo, A., Yuan, M. and Yankner, B. A. (1998). Nature Medicine 4, 827-831.
31. Hacia, J. G. (2001). Genome of the apes, Trends in Genetics 17, 637-645.
32. Hantraye, P. (1998). Modeling dopamine system dysfunction in experimental animals, Nuclear Med. Biol. 25, 721-728.
33. Harding, A. (2004). More compounds failing phase I. FDA chief warns that high drug attrition rate is pushing up the cost of drug development, The Scientist (6 August).
34. Heywood, R. (1990). Clinical toxicity - could it have been predicted? In: Animal Toxicity Studies: Their Relevance for Man, Lumley, C. E. and Walker, S. R. (Eds), pp. 57-67. Quay, Lancaster, UK.
35. Hodgson, J. (2001). ADMET - turning chemicals into drugs, Nature Biotechnol. 19, 722-726.
36. Home Office Primates Stakeholder Forum (2004): Rapporteur's Report. Website: http://www.homeoffice.gov.uk/docs4/apc_non_human_primates.pdf
37. House of Lords Select Committee on Animals in Scientific Procedures (2002). HL150-I, 16 July.
38. Huang, J., et al. (2000). A modified transorbital baboon model of reperfused stroke, Stroke 31, 3054-3063.
39. Kaufman, S. R. (1991). UR researchers refused to debate, Democrat and Chronicle, Rochester, NY, July 19.
40. Kaufman, S. R. (1994). Animal protection and medical science [letter], Lancet 343, 1574.
41. Kaufman, S. R., Cohen, M. J. and Simmons, S. (1996). In: Shortcomings of AIDS-Related Animal Experimentation. Medical Research Modernization Committee, New York [www.mrmcmed.org/aids.html].
42. Koopman, G., et al. (1999). The relative resistance of HIV type 1-infected chimpanzees to AIDS correlates with the maintenance of follicular architecture and the absence of infiltration by CD8+ cytotoxic T lymphocytes, AIDS Res. Hum. Retroviruses 15, 365-373.
43. Lanford, R. E., Bigger, C., Bassett, S. and Kimpel, G. (2001). The chimpanzee model of hepatitis C virus infections, ILAR Journal 42, 117-126.
44. Lazarou, J., Pomeranz, B. H. and Corey, P. N. (1998). Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies, J. Amer. Med. Assocn. 279, 1200-1205.
45. Lindholm, D. (1997). Models to study the role of neurotrophic factors in neurodegeneration, J. Neural Transm. Suppl. 49, 33-42.
46. Lumley, C. E. and Walker, S. R. (1990). In: Animal Toxicity Studies: Their Relevance for Man, p. 73. Quay, Lancaster, UK.
47. Lydon, N. B., Adams, B., Poschet, J. F., et al. (1990). An E. coli expression system for the rapid purification and characterization of a v-abl tyrosine protein kinase, Oncogene Research 5, 161-173.
48. Major, M. E. and Feinstone, S. M. (2000). Characteristics of hepatitic C infectious clones in chimpanzees, Curr. Topics Microbiol. Immunol. 242, 279-298.
49. Mann, R. D. (1984), Modern Drug Use: An Enquiry on Historical Principles. MTP Press, Lancaster, UK.
50. Marshall, E. (2000). Gene thereapy on trial, Science 288, 951-957.
51. Mitsuya, H., Weinhold, K. J., Furman, P. A., et al. (1985). 3′-Azido-3′deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro, Proc. Natl Acad. Sci. USA 82, 7096-7100.
52. Mufson, E. J., Kahl, U., Bowser, R., Mash, D. C., Kordower, J. H. and Deecher, D. C. (1998). Galanin expression within the basal forebrain in Alzheimer's disease. Comments on therapeutic potential, Ann. N Y Acad. Sci. 863, 291-304.
53. Nath, B. M., et al. (2000). The chimpanzee and other non-human-primate models in HIV-1 vaccine research, Trends Microbiol. 8, 426-431.
54. Neff, S. (1989). Clinical relevance of stroke models, Stroke 20, 699-701.
55. NHP Study website: http://www.nhpstudy.com/call_for_evidence.pdf
56. Nimchinsky, E. A., Gilissen, E., Allman, J. M., Perl, D. P., Erwin, J. M. and Hof, P. R. (1999). A neuronal morphologic type unique to humans and great apes, Proc. Natl Acad. Sci. USA 96, 5268-5273.
57. Nuffield Council on Bioethics (2005). The Ethics of Research Involving Animals, http://www.nuffieldbioethics.org.
58. Olson, H., et al. (2000). Concordance of the toxicity of pharmaceuticals in humans and animals, Regul. Toxicol. Pharmacol. 32, 56-67.
59. Palfreyman, M. G., Charles, V. and Blander, J. (2002). The importance of using human-based models in gene and drug discovery, Drug Discovery World, 33-40, [Personal communication from professional statistician].
60. Pharmagene website: http://www.pharmagene.com/ (Active programmes).
61. Roberts, N. A., Martin, J. A., Kinchington, D., et al. (1990). Rational design of peptide-based HIV proteinase inhibitors, Science 248, 358-361.
62. Rosenk, H. R. and Martin, P. (2000). Hepatitis B and C in the liver transplant recipient, Seminars Liver Dis. 20, 465-480.
63. Rouse, M. S. and Wilson, W. R. (1999). General methodologies for animal models, in: Handbook of Animal Models of Infection, p. 9. Academic Press.
64. Ruvolo, M. (2004). Comparative primate genomics: the year of the chimpanzee, Curr. Opin. Genet. Dev. 14, 650-656.
65. Sabin, A. (1984). Statement before the Subcommittee on Hospitals and Health Care, Committee on Veterans Affairs, House of Representatives, April 26, serial no. 98-48.
66. Schardein, J. L. (1993). Chemically Induced Birth Defects, 2nd edn. Marcel Dekker, New York.
67. Schein, P. S., Davis, R. D., Carter, S., Newman, J., Schein, D. R. and Rall, D. P. (1970). The evaluation of anticancer drugs in dogs and monkeys for the prediction of qualitative toxicities in man, Clin. Pharmacol. Ther. 11, 3-40.
68. Seelmeier, S., et al. (1988). Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A, Proc. Natl Acad. Sci, USA 85, 6612-6616.
69. Sibal, L. R. and Samson, K. J. (2001). Nonhuman primates: A critical role in current disease research, ILAR Joumal 42, 74-84.
70. Smaglik, P. (1999). AIDS vaccine researchers turn from chimps to monkeys, The Scientist 13, 7, August 16th.
71. Smith, D., Trennery, P., Farningham, D. and Klapwijk, J. (2001). The selection of marmoset monkeys, Callithrix jacchus, in pharmaceutical toxicology, Laboratory Animals 35, 117-130.
72. Snowdon, D. A., Greiner, L. H., Mortimer, J. A., Riley, K. P., Greiner, P. A. and Markesbery, W. R. (1997). Brain infarction and the clinical expression of Alzheimer disease. The Nun Study, J. Amer. Med. Assocn. 277, 813-817.
73. Soudeyns, H., Yao, X.-J., Gao, Q., et al. (1991). Anti-human immunodeficiency virus type 1) activity and in vitro toxicity of 2′-deoxy-3′-thiacytidine (BCH 189), a novel heterocyclic nucleoside analog, Antimicrobial Agents and Chemotherapeutics 35, 1386-1390.
74. Spriet-Pourra, C. and Auriche, M. (1994). Drug Withdrawal from Sale, 2nd edn. Scrip Reports, PJB Publications, New York, USA.
75. St. George-Hyslop, P. H. and Westaway, D. A. (1999). Alzheimer's disease. Antibody clears senile plaques, Nature 400, 116-117.
76. Steinberg, D. (2002). Companies halt first Alzheimer vaccine trial, The Scientist 16, 22, April 1st.
77. Stott, J. and Almond, N. (1995). Assessing animal models of AIDS, Nature Medicine 1, 295-297.
78. Sun, B. S., Pan, J., Clayton, M. M., Liu, J., Yan, X., Matskevich, A. A., Strayer, D. S., Gerber, M. and Feitelson, M. A. (2004). Hepatitis C virus replication in stably transfected HepG2 cells promotes hepatocellular growth and tumorigenesis, J. Cell Physiol. 201, 447-458.
79. UK Human Tissue Bank website: http://www.ukhtb.org
80. US Food and Drug Administration website: http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.html
81. Vacca, J. P., et al. (1994). L-735,524: an orally bioavailable human immunodeficiency virus type 1 protease inhibitor, Proc. Natl. Acad. Sci, USA 91, 4096-4011.
82. Watanabe, H., et al. (2004). DNA sequence and comparative analysis of chimpanzee chromosome 22, Nature 429, 382-388.
83. Wiebers, D. O., Leaning, J. and White, R. D. (1994). Animal protection and medical science, Lancet 343, 902-904.
84. Wiebers, D. O., Adams, H. P. Jr. and Whisnant, J. P. (1990a). Animal models of stroke: are they relevant to human disease? Stroke 21, 1-3.
85. Wiebers, D. O., Whisnant, J. P., Sandok, B. A. and O'Fallon, W. M. (1990b). Prospective comparison of a cohort with asymptomatic carotid bruit and a population-based cohort without carotid bruit, Stroke 21, 984-988.
86. Wilson, C. (2003). HIV vaccine hopes still high, New Scientist 2385, 8 March.
87. Wyand, M. S. (1992). The use of SIV-infected rhesus monkeys for the preclinical evaluation of AIDS drugs and vaccines, AIDS Res. Human Retroviruses 8, 349-356.
88. Xceleron website: http://www.xceleron.co.uk/metadot/ index.pl?id=2224&isa=Newsitem&op=show
89. Young, E. (2002). Alzheimer's vaccine trial suspended, The New Scientist, 22 January.
90. Zanetti, A. R., Tanzi, E., Paccagnini, S., Principi, N., Pizzocolo, G., Caccamo, M. L., D'Amico, E., Cambie, G. and Vecchi, L. (1995). Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission, Lancet 345, 289-291.
91. Zhong, J., Gastaminza, P., Cheng, G., Kapadia, S., Kato, T., Burton, D. R., Wieland, S. F., Uprichard, S. L., Wakita, T. and Chisari, F. V. (2005). Robust hepatitis C virus infection in vitro, Proc. Nat. Acad. Sci. USA 102, 9294-9299.